Stocksigma LogoStocksigma Logo

Gufic Biosciences Ltd - Financial Result for the Quarter ended 30th Sep'26 (Consolidated, INR Lakh)

■ Revenue: 28,827 (+21.6% YoY | +10.5% QoQ) ■ EBITDA: 4,849 (+28.1% YoY | +4.1% QoQ) ■ EBITDA Margin (%): 16.8 (+86 bps YoY | -105 bps QoQ) ■ PAT: 2,347

Gufic Biosciences Ltd - Financial Result for the Quarter ended 30th Sep'26 (Consolidated, INR Lakh)

Gufic Biosciences Ltd · Outcome · 15 Nov 2026, 1:41 am

Gufic Biosciences Ltd - Financial Result for the Quarter ended 30th Sep'26 (Consolidated, INR Lakh) ■ Revenue: 28,827 (+21.6% YoY | +10.5% QoQ) ■ EBITDA: 4,849 (+28.1% YoY | +4.1% QoQ) ■ EBITDA Margin (%): 16.8 (+86 bps YoY | -105 bps QoQ) ■ PAT: 2,347 (+39.5% YoY | +5.2% QoQ) ■ EPS (INR): 2.34 (+39.3% YoY | +5.4% QoQ)

Original exchange filing (PDF)

More announcements from Gufic Biosciences Ltd

All Gufic Biosciences Ltd announcements